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Chronic wound infections are a major burden to both society and the health care industry.
Bacterial biofilms are the major cause of chronic wound infections and are notoriously
recalcitrant to treatments with antibiotics, making them difficult to eradicate. Thus, new
approaches are required to combat biofilms in chronic wounds. One possible approach
is to use drug combination therapies. Manuka honey has potent broad-spectrum
antibacterial activity and has previously shown synergistic activity in combination with
antibiotics against common wound pathogens, including Staphylococcus aureus. In
addition, manuka honey exhibits anti-biofilm activity, thereby warranting the investigation
of its potential as a combination therapy with antibiotics for the topical treatment of
biofilm-related infections. Here we report the first use of MacSynergy II to investigate
the response of established S. aureus (strain NCTC 8325) biofilms to treatment by
combinations of Medihoney (medical grade manuka honey) and conventional antibiotics
that are used for preventing or treating infections: rifampicin, oxacillin, fusidic acid,
clindamycin, and gentamicin. Using checkerboard microdilution assays, viability assays
and MacSynergy II analysis we show that the Medihoney-rifampicin combination
was more effective than combinations using the other antibiotics against established
staphylococcal biofilms. Medihoney and rifampicin were strongly synergistic in their ability
to reduce both biofilm biomass and the viability of embedded S. aureus cells at a level
that is likely to be significant in vivo. Other combinations of Medihoney and antibiotic
produced an interesting array of effects: Medihoney-fusidic acid treatment showed
minor synergistic activity, and Medihoney-clindamycin, -gentamicin, and -oxacillin
combinations showed overall antagonistic effects when the honey was used at
sub-inhibitory concentration, due to enhanced biofilm formation at these concentrations
which could not be counteracted by the antibiotics. However, these combinations were
not antagonistic when honey was used at the inhibitory concentration. Confocal scanning
laser microscopy confirmed that different honey-antibiotic combination treatments
Liu et al. Medihoney-Antibiotic Synergism against Staphylococcal Biofilms
could eradicate biofilms. Our results suggest that honey has potential as an adjunct
treatment with rifampicin for chronic wounds infected with staphylococcal biofilms. We
also show that MacSynergy II allows a comprehensive examination of the synergistic
effects of honey-antibiotic combinations, and can help to identify doses for clinical use.
Keywords: medihoney, Staphylococcus aureus, manuka, antibiotic, synergy, biofilm, MacSynergy II, natural
product
INTRODUCTION
The incidence, cost, morbidity, and mortality associated with
chronic wound infections are a major burden to both society
and the health care industry. In Australia alone, an estimated
400,000 people suffer from chronic wounds or ulcers at an
estimated cost of AU$2.8 billion annually and ∼AU$10, 000
per patient per year (Graves and Zheng, 2014; Whitlock et al.,
2014). In the United States, chronic wounds affect 6.5 million
people and cost US$25 billion yearly (Sen et al., 2009). Although
bacteria living in both planktonic (free-living) and biofilm states
can cause infections in wounds, biofilms cause most chronic
wound infections, leading to significant delays in wound healing
(Percival et al., 2012; Zhao et al., 2013). Biofilms are up to
1,000 times more recalcitrant to treatment with antibiotics and
biocides than planktonic cells (Hoyle and Costerton, 1991; Hall-
Stoodley and Stoodley, 2009; Lebeaux et al., 2014), making them
difficult to eradicate using antibiotic therapy.
One possible approach to eradicate bacterial biofilms is to
use drug combination therapy, which can widen the therapeutic
window, lower the dosage, and reduce the development of
antimicrobial resistance (Bjarnsholt et al., 2013; Wu et al., 2015).
Honey, a natural product that exhibits potent broad-spectrum
antibacterial (bactericidal) activity (Carter et al., 2016) has
shown synergistic activity in combination therapy with certain
antibiotics for planktonic cells (Jenkins and Cooper, 2012b;
Müller et al., 2013; Liu et al., 2015).
Manuka honey, derived from nectar collected by honey bees
(Apis mellifera) foraging on Leptospermum scoparium plants,
is the predominant antimicrobial honey in clinical use. Key
to manuka honey is the reactive dicarbonyl methylglyoxal
(MGO) (Adams et al., 2008; Mavric et al., 2008) which, together
with high sugar content, low water activity, low pH, and the
formation of hydrogen peroxide (H2O2) upon dilution, produces
potent antibacterial activity (Allen et al., 1991; Bogdanov et al.,
2008). Honey also has a low propensity for bacterial resistance
(Blair et al., 2009; Cooper et al., 2010), a highly attractive
property given the global antibiotic resistance crisis. The need for
alternative strategies to treat infections, particularly by reducing
or avoiding the use of our most potent antibiotics for superficial
infections, has never been greater. Honey dressings and wound
gels, licensed by regulatory authorities in many countries, are
currently available for clinical use. However, honey remains
under-utilized as a wound treatment as health professionals
claim more experimental data are required to support clinical
use (Cooper and Jenkins, 2012; Carter et al., 2016). A recent
Cochrane review concluded that there is currently insufficient
robust evidence to determine the value of honey as a treatment
for chronic wounds, although it notes that honey does heal
partial thickness burns and infected post-operative wounds more
quickly than conventional treatments (Jull et al., 2015).
Staphylococcus aureus is a common cause of chronic wound
infections (Bowler et al., 2001).We and others have demonstrated
strong synergy between manuka honey and rifampicin, oxacillin,
and clindamycin in inhibiting the growth of planktonic cells
and preventing biofilm formation by different S. aureus strains
[including methicillin-resistant S. aureus (MRSA)] (Jenkins and
Cooper, 2012a,b; Müller et al., 2013; Liu et al., 2015). In
some cases, antibiotic-resistant strains became markedly more
sensitive to antibiotics in the presence of manuka honey (Müller
et al., 2013; Lu et al., 2014; Liu et al., 2015). However, infected
chronic wounds typically have established biofilms, and reducing
or eliminating these is of clinical importance. Manuka honey
alone can reduce established S. aureus biofilms (Lu et al., 2014)
but this has not yet been tested in combination with antibiotics.
This study therefore set out to investigate interactions between
honey and antibiotics on established biofilms.
Establishing drug interactions can be challenging and there
are various models available (Greco et al., 1995). To date,
interaction studies using honey have employed the fractional
inhibitory concentration index (FICI) (Jenkins and Cooper,
2012a,b; Müller et al., 2013; Liu et al., 2015). However, this
has disadvantages when assessing honey-antibiotic interactions
because (1) the minimum inhibitory concentration (MIC) for
honey is relatively high compared to antibiotics and expressed
using different units, i.e., percentage weight per volume (%
w/v) as opposed to µg/ml; (2) synergy by FICI requires a dose
reduction in both agents, and honey-antibiotic combinations
often lead to amarked reduction in the dose required of antibiotic
but not honey (Liu et al., 2015); and (3) FICI is a two-dimensional
(2-D) analysis whereby one variable must be constant and as
such, it does not allow comprehensive dose-response analyses,
potentially missing or underestimating important interactions
(Greco et al., 1995). To overcome these limitations, models have
been developed that enable three variables (concentrations of
both drugs and the biological effect) to be analyzed at once.
Plotting the dose-response in a three-dimensional (3-D) space
allows the identification of both synergistic and antagonistic
interactions across a range of concentrations for both drugs.
Here we evaluate the response of established S. aureus NCTC
8325 biofilms to treatment by combinations of Medihoney and
conventional antibiotics frequently used systemically to treat
infected chronic wounds: rifampicin, oxacillin, fusidic acid,
clindamycin, and gentamicin, using MacSynergy II to construct
a 3-D drug interaction surface (Prichard et al., 1991). We show
that the Medihoney-rifampicin combination was most effective
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combination at eradicating established staphylococcal biofilms.
The results of this study suggest that honey could be used
in combination therapy with rifampicin for chronic wounds
with established biofilms caused by Staphylococcus (including
MRSA), adding weight to the synergistic anti-staphylococcal
activity of this combination treatment previously reported
against planktonic cells and biofilm prevention (Müller et al.,
2013; Liu et al., 2015). We also show that MacSynergy II allows
identification of doses with synergistic activity that are otherwise
overlooked in conventional 2-D analyses (FICI).
MATERIALS AND METHODS
Bacterial Strain, Antibiotics, and Honey
Laboratory reference strain S. aureus NCTC 8325 was used
in this study as it has the ability to form robust biofilms
on abiotic surfaces (Lu et al., 2014) and was used in our
earlier studies of biofilm and planktonic cell responses to
Medihoney and antibiotics (Müller et al., 2013; Liu et al., 2015).
Tryptone soya broth (TSB, Oxoid) was used for all growth
assays and biofilm treatment assays. Antibiotics (rifampicin,
fusidic acid, clindamycin hydrochloride, gentamicin sulfate
solution and oxacillin sodium salt) were purchased from Sigma-
Aldrich. Medihoney, a commercially available medical-grade
honey (predominantly derived from L. scoparium blended with
some Kunzea ericoides honey), was provided by Comvita Ltd,
New Zealand. The honey was stored in the dark at 4◦C and
was freshly diluted for use in every assay. The concentrations
of the two major antimicrobial components (MGO, H2O2)
were tested and were equivalent to previously reported levels
(MGO: 776 mg/kg; H2O2: 0.31 µmol/h) (Lu et al., 2013, 2014).
Honey concentrations are reported in this study as % weight per
volume (w/v).
Determination of MICs for Antimicrobial
Agents and Their Ability to Reduce
Established Biofilms
The MICs of Medihoney and antibiotics against planktonic
S. aureus were determined via broth microdilution assays, as
previously described (Liu et al., 2015). The MIC was assessed
as the lowest concentration that inhibited 99% of S. aureus
compared to the untreated (growth) control.
The ability of antimicrobial agents to reduce established
S. aureus biofilms was assessed using a biofilm treatment
assay as previously described (Lu et al., 2014). Briefly, biofilms
were established in each well of a sterile 96-well flat-bottomed
microtiter-plate by inoculating approximately 107 CFU/mL of
S. aureus in TSB and incubating at 37◦C for 24 h without shaking.
Biofilms were then rinsed twice with sterile phosphate buffered
saline (PBS) and treated with either Medihoney (concentrations
ranging from 1–32%, equivalent to 0.125–4 × MIC, in two-
fold increments) or antibiotics (at concentrations that were 1,
3, 5, 10, 30, 50, and 100 × MIC) and incubated for a further
24 h at 37◦C. Following incubation, the liquid content from each
well was carefully removed with a pipette and the wells washed
twice by gently rinsing with PBS to remove loosely attached
planktonic cells. The remaining biofilms were dry-fixed onto
the plates by air-drying at 65◦C for 1 h and stained with 0.2%
crystal violet solution for 1 h at room temperature. Excess crystal
violet solution was decanted and the plates rinsed with sterile
reverse osmosis (RO) water and briefly dried before solubilising
the stained biofilm with 30% acetic acid. The OD (595 nm)
of each well was measured on an automated microtiter plate
reader (VersaMax, Molecular Devices, California, USA) and the
readings were converted into percentage of biofilm reduction
based on the untreated control wells where no antibiotic or
Medihoney was applied.
Checkerboard Microdilution Assay to
Assess Medihoney-Antibiotic Interactions
against S. aureus Biofilms
S. aureus biofilms established as above were washed with sterile
PBS and each pair of antimicrobial agents (Medihoney and
antibiotic) was added across the x and y dimensions of the
96-well plate in two-fold serial dilutions with TSB medium.
Concentrations tested ranged from 0.25–4 × MIC for each
antibiotic and from 0.125–8×MIC (i.e., 1–32%w/v)Medihoney.
Each combination was repeated in the adjacent horizontal
wells to provide technical duplicates, and the experiment was
performed on 3 different days to provide experimental replicates.
The experiment included two treatment controls, where either
antibiotic or Medihoney was used alone, and a negative control
(media only).
Statistical Analysis of Honey-Antibiotic
Interactions Using MacSynergy II
Dose-response curves were plotted to determine if a honey-
antibiotic combination pair reduced the biofilm biomass more
than either honey or antibiotic used alone. MacSynergy II
(Prichard et al., 1991) is based on a Bliss Independence null
reference model and uses the dose response curves of the
individual antimicrobials (honey or antibiotic) to calculate
theoretical additive interactions and to produce a predicted
additive surface, with the assumption that the agents act
independently (Prichard and Shipman, 1990). An interaction is
defined as synergistic if the observed surface is greater than the
predicted additive surface when confidence intervals are set at
95%. Antagonism is defined as the observed surface being less
than the predicted additive surface.
Viability Assay Using Bactiter-Glo
The viability of biofilms remaining post-treatment was evaluated
using the BacTiter-GloTM (Promega, Madison WI) assay, which
measures the production of adenosine triphosphate (ATP) by
metabolically active bacterial cells using a luminescent reporter.
As ATP production is relatively constant across many different
growth conditions (Schneider and Gourse, 2004), ATP-based
assays are used routinely to monitor the presence of active
bacteria and have been applied to biofilms (Takahashi et al., 1988;
Monzón et al., 2001; Romanova et al., 2007; Sule et al., 2009; Lu
et al., 2014).
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After honey and antibiotic treatment of established biofilms as
outlined above, BacTiter-Glo reagent (20µl) was added into each
well followed by 100 µl of TSB. The bioluminescence reaction
was started by the addition of the BacTiter-Glo reagent and
incubation in the dark for 10min at 37◦C. Bioluminescence
was determined in a Tecan Infinite 200 PRO series microplate
reader (Tecan Group, Switzerland). To allow for consistency in
incubation times, a single 96-well microtiter-plate was processed
at a time. Statistical analysis to determine significant differences
in viability following treatments was performed using one-way
ANOVA with the Tukey test in GraphPad Prism (version 6; CA,
USA) with statistical significance set at p <0.05.
Visual Assessment of Biofilm Reduction
Using Confocal Microscopy
For confocal microscopy, treatments were set up as described
above, but in black polystyrene 96-well microtiter plates
(µClear R© bottom Cellstar R©; Greiner Bio-One, France).
Following treatment, the plate was washed three times with PBS
and cells within the biofilm structure were fluorescently stained
with 2.5µM SYTOTM 9 Stain (Invitrogen, CA, USA) and 4.3µM
propidium iodine (PI) (Becton Dickinson, NJ, USA), which
identify live and dead cells, respectively, in the biofilm structure.
After 30min of incubation in the dark at room temperature, the
wells were washed with PBS and fixed with 4% paraformaldehyde
(Sigma-Aldrich, MO, USA) for 15min. The wells were then
rinsed and stored in PBS for imaging. Biofilms were imaged
using confocal laser scanning microscopy (CLSM) imaging on
a Nikon A1 confocal microscope (with 40X Plan Fluor ELWD,
0.6 N/A objective). The SYTO R© 9 and PI fluorophores were
excited at 488 and 561 nm, and the emissions were collected
at 500–550 nm and 570–620 nm, respectively. Representative
image stacks of each treatment were acquired at a resolution
of 1024 × 1024 pixels and biofilm image reconstructions were
performed using NIS-elements (version 10, Nikon Instruments
Inc., USA).
RESULTS
Minimum Inhibitory Concentrations and
Anti-Biofilm Activity of Medihoney and
Antibiotics against S. aureus
We used broth microdilution growth assays to determine the
individual MICs of Medihoney and selected antibiotics against
planktonic growth of S. aureusNCTC 8325 (Table 1). Consistent
with our previous studies (Lu et al., 2013, 2014;Müller et al., 2013;
Liu et al., 2015), the MIC of Medihoney was 8% w/v. The MICs
for the selected antibiotics against S. aureus are comparable to
those reported in the literature (O’Neill et al., 2002; Hanssen et al.,
2004; Didier et al., 2011).
The individual effect of Medihoney and selected antibiotics
on the biomass of established S. aureus biofilms was determined
using a biofilm treatment assay based on crystal violet staining
(Table 1). The established biofilm decreased in biomass when
treated with Medihoney at 1–4×MIC or each of the five selected
TABLE 1 | Summary of the results of Medihoney and antibiotic treatments on S. aureus.
Checkerboard combination assay with Medihoney





















Medihoney 8 16 N/A N/A N/A N/A N/A



















Gentamicin 0.626 >62.5 No N/A Antagonistic N/A N/A
Oxacillin 0.16 0.48 No N/A Antagonistic N/A N/A
aMIC: minimum inhibitory concentration, expressed as the mean % weight per volume for honey or µg/ml for antibiotics from three separate experiments.
bData presented in Figure 1. Results expressed as concentration of agent required to achieve ≥85% eradication compared to the untreated control, % weight per volume for honey or
µg/ml for antibiotics.
cData presented in Figure 2, concentrations expressed as % weight per volume for honey and µg/ml for antibiotic.
dData presented in Figure 3, concentrations expressed as % weight per volume for honey and µg/ml for antibiotic.
eData presented in Figure 4, left panel. Statistical significance determined using one-way ANOVA, p <0.05.
N/A, not applicable.
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antibiotics at 1–100 × MIC. The extent of biofilm reduction
differed for the different agents. When honey was used at the
MIC (8% w/v), biofilm biomass was reduced by 25%. Thus, at
the MIC honey is less effective than rifampicin, fusidic acid,
clindamycin, and oxacillin at reducing biofilm biomass (reduced
by 65, 55, 65, and 80%, respectively), but more effective than
gentamicin (reduced by 15%). However, at 2 × MIC (16%
w/v) honey was effective at reducing the established biofilm
by 90%. Of the antibiotics, oxacillin was the most effective
giving ∼90% reduction when used at 3 × MIC and up to 95%
reduction when used at 5 × MIC. Clindamycin and fusidic acid
required 30 × MIC for a reduction of ∼90%, while gentamicin
and rifampicin did not reduce the biofilm to this level at any
concentration tested, and plateaued at ∼80% reduction at 50 ×
MIC. Complete biofilm eradication (i.e., 100% reduction) was
not observed for any of the antibacterial agents, even at the
highest concentrations tested (4 × MIC for honey; 100 × MIC
for antibiotics; Figure 1); however a reduction of biofilm by
≥85% was defined as eradication as consistent with other biofilm
studies.
Interactions between Medihoney and
Antibiotics on Established S. aureus
Biofilms
We used a checkerboard microdilution assay based on crystal
violet staining to determine whether the treatment of established
biofilms with combinations of Medihoney and a selected
antibiotic would reduce biofilm biomass more than treatment
with Medihoney or antibiotic alone. In the combinatorial
FIGURE 1 | Dose response curves for established S. aureus biofilms treated
with Medihoney and antibiotics. Biofilms were established during 24 h static
incubation before treatment for 24 h with either Medihoney or antibiotic at a
range of concentrations. Biofilm biomass was then quantified using crystal
violet staining. The biofilm remaining is expressed as a percentage relative to
that of the untreated control, which is set at 100%. Error bars represent the
standard error of the mean (SEM) of triplicate samples performed in duplicate
on 3 different days.
treatments, Medihoney was used at 0.125–4×MIC (1–32% w/v)
and each antibiotic was used at 0.25–4 × MIC (in two-fold
increments), and the results are summarized as dose-response
curves (Figure 2).
The established biofilms increased in biomass when
Medihoney was used at concentrations below the MIC (1–4%
w/v; 0.125–0.5 × MIC) and low levels of the antibiotics largely
paralleled this pattern. We noted a similar trend previously when
this S. aureus strain was treated with Medihoney (Lu et al., 2014).
The effect of Medihoney-antibiotic combinations on
established biofilms varied depending on the antibiotic used
and on the concentrations of the agents (i.e., honey and
antibiotic; Figure 2 and Table 1). The most striking positive
effect was observed for the Medihoney-rifampicin combination,
where biofilm biomass reduction was much larger than what
was achieved by Medihoney or rifampicin used alone. This
was observed across multiple concentration combinations of
Medihoney-rifampicin, including concentrations below the
MIC. For example, 8% w/v Medihoney (MIC) on its own
reduced biofilm biomass by < 10% but this increased to 85%
when combined with sub-inhibitory rifampicin concentrations
(0.02µg/ml; 0.5 × MIC). Sub-inhibitory concentrations of
Medihoney (2 and 4% w/v; 0.25–0.5 × MIC) and rifampicin
(≥0.02µg/ml; 0.5 × MIC) when used together reduced biofilm
biomass by at least 70%. For both the Medihoney-clindamycin
and Medihoney-fusidic acid combinations, substantial biofilm
reduction (> 70%) was observed when the Medihoney was
used at the MIC (8%) and antibiotics used at any concentration,
including sub-inhibitory ones (0.02–0.04µg/ml; 0.25 0 0.5 ×
MIC). No significant reduction in biofilm biomass was observed
for either theMedihoney-oxacillin or theMedihoney-gentamicin
combinations compared to that achieved by the antibiotic alone.
MacSynergy II Plots Reveal the Landscape
of Synergy and Antagonism in
Medihoney-Antibiotic Combinations on
Established Biofilms
To better visualize the nature and the degree of interactions
that occur between Medihoney and the selected antibiotics in
the treatment of established biofilms, we performed a rigorous
quantitative analysis of their interaction using MacSynergy
II (Prichard and Shipman, 1990). The program uses the
spectrometric absorbance data generated by the checkerboard
dilution assays and plots a landscape of the dose-response,
rather than a curve, enabling a visual representation of the
combined doses where the response is synergistic (peaks),
additive (horizontal plane) or antagonistic (trough; Figure 3,
Table 1).
For the Medihoney-rifampicin combinations, all interactions
were above the plane of additivity (Figure 3A), and the
overall synergy/antagonism volumes were 305/−6 µM2%
(Supplementary Table 1). Thus, the observed size of the
synergy derived from the 95% confidence interval (based
on Bonferroni adjustment) indicated a strong synergistic
interaction between Medihoney and rifampicin across a
range of concentrations (volumes >50 denote synergy).
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FIGURE 2 | The ability of Medihoney-antibiotic combinations to remove biofilm varies greatly with different antibiotics Medihoney-rifampicin combinatorial treatment
showed the greatest reduction in biofilm even when the antibiotic was used at sub-inhibitory levels. Medihoney combined with either fusidic acid or clindamycin also
reduced biofilm substantially. Combinations of Medihoney with gentamicin or oxacillin did not reduce biofilm any more than that which was achieved by the antibiotic
alone. Error bars represent the standard error of the mean (SEM) of triplicate samples performed in duplicate. The MIC of each antibacterial agent is shown in bold
and boxed.
Moreover, this is probably important in vivo (volumes >100
identified as having likely significance in vivo Prichard and
Shipman, 1990). The Medihoney-fusidic acid combination
produced a complex interaction profile consistent with the
curves presented in Figure 2, with synergy (peaks) at high
concentrations of both agents and antagonism (troughs) at low
concentrations (Figure 3B). The observed synergy volumes
seen when the higher concentrations of Medihoney-fusidic
acid were used corresponded to a volume of 42.49 µM2%
(Supplementary Table 1), considered significant but minor
(Prichard and Shipman, 1990). The antagonism trough (volume
−27.24µM2%) observed with 1% Medihoney−0.02µg/ml
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FIGURE 3 | Three-dimensional dose-response plots highlight substantial differences in the effect of Medihoney-antibiotic combinations on established S. aureus
biofilms Interaction surfaces were calculated based on response surface analysis using MacSynergy II. Additive interactions appear as a horizontal plane at 0%
inhibition. Peaks of statistically significant synergy (positive value) or antagonism (negative value, troughs) that deviate significantly from the theoretical expected
additive interaction surface are shown, with different colors indicating the level of synergy or antagonism. Antibiotic concentrations (x-axis) are in µg/ml and honey
(z-axis) in % weight per volume. Plots show combinations of Medihoney with: (A) rifampicin; (B) fusidic acid; (C) clindamycin; (D) gentamicin; and (E) oxacillin.
fusidic acid (equivalent to 0.125 and 0.25 × MIC), respectively,
was not significant.
The Medihoney-clindamycin combination showed a
small peak of synergy (Figure 3C; volume 23 µM2%,
Supplementary Table 1) and a more pronounced antagonism
volume of −63 µM2%, identifying concentrations that are
potentially useful (i.e., synergistic) and those that should
be avoided (i.e., antagonistic). Finally, MacSynergy analysis
of the Medihoney-gentamicin and Medihoney-oxacillin
combinations demonstrate strong antagonistic effects for
almost all concentration combinations (Figures 3D,E) with
overall antagonism volumes of −422.17 and −1278.96 µM2%,
respectively (Supplementary Table 1). This is in agreement with
the dose-response curves where no positive interactions were
detected by these combined treatments on established biofilms
(Figure 2).
Effect of Medihoney and Antibiotic
Combinations on Biofilm Cell Viability and
Biofilm Structure
Although the checkerboard microdilution assay using crystal
violet staining revealed certain Medihoney and antibiotic
combinations resulted in significant changes to established
Frontiers in Microbiology | www.frontiersin.org 7 January 2018 | Volume 8 | Article 2653
Liu et al. Medihoney-Antibiotic Synergism against Staphylococcal Biofilms
biofilm biomass, this assay does not assess the viability of cells
remaining within the biofilm structure (Bauer et al., 2013). To
quantitatively assess biofilm cell viability we used the BacTiter-
Glo assay, which measures ATP levels as a proxy for viability. We
have previously correlated the luminescent signal from the ATP
levels to S. aureus cell numbers (CFU/ml) via direct enumeration
(Lu et al., 2014). The effect of the treatment combinations on
established biofilms at the cellular level was analyzed using
confocal scanning laser microscopy with the “live” cell stain,
SYTOTM 9. We performed these experiments using treatments
with honey combined with rifampicin, clindamycin, or fusidic
acid since these antibiotics showed some synergy with honey in
the dose-response curves and MacSynergy assays (Figures 2, 3).
Cells within the biofilm that remained following treatment
with synergistic concentrations of Medihoney-rifampicin had
a significant reduction in viability compared to cells within
untreatedbiofilms. For example, 8%w/vMedihoney+0.01µg/ml
rifampicin gave > 60% reduction in viability; and 8% w/v
Medihoney + 0.02µg/ml rifampicin gave a 90% reduction
(p <0.005, Figure 4A, left panel). Similarly, a reduction in
density of cells was observed using confocal laser scanning
microscopy (Figure 4A, right panel). The Medihoney-rifampicin
combination thus demonstrated strong synergistic effects in both
reducing biofilmbiomass and in reducing the viability and density
of cells within the biofilm that remained following treatment.
These results are consistent with the checkerboard analysis.
Despite minor synergism in reducing biofilm biomass
observed when Medihoney (8% w/v) was combined with
0.02µg/ml or 0.04µg/ml fusidic acid (Figure 2), the cells in the
remaining biofilm did not show reduced viability compared to
the single-treatment controls (i.e., cells in biofilms treated with
the same concentrations of Medihoney or fusidic acid alone).
Similarly, this combination did not produce a significant decrease
in biofilm live-cell density relative to the controls (Figure 4B,
right panel). This suggests that these treatment combinations
may be effective in reducing biofilm biomass but are less effective
as a bactericidal against cells in an established biofilm.
In contrast, Medihoney-clindamycin, which was overall
antagonistic in its effects on biofilm biomass (Figures 2, 3), did
significantly reduce the viability of cells in the remaining biofilm
when compared to cells within untreated biofilms or biofilms
treated with clindamycin or Medihoney alone (Figure 4C, left
panel; p < 0.05). Further, confocal microscopy showed a marked
reduction in density of the remaining biofilm (Figure 4C, right
panel).
DISCUSSION
The incidence of non-healing chronic wounds within the
community is increasing largely due to rising rates of diabetes and
obesity, and the increase in the aging population (Sen et al., 2009).
Chronic wounds harbor bacterial populations that commonly
exist as biofilms (Dowd et al., 2008). This makes chronic wounds
inherently difficult to treat with antibiotics because bacteria
present in biofilms are far more tolerant of antibiotics than
planktonic bacteria (Percival et al., 2012; Zhao et al., 2013).
Therefore, effective treatments of chronic wounds need to be able
to reduce the existing biofilms in the wound and simultaneously
prevent the formation of new biofilms.
Honey-antibiotic treatments of S. aureus cells have shown
promise in previous studies, whereby the inhibition of planktonic
bacterial cells and prevention of biofilms was improved when
honey was used in combination with certain antibiotics (Müller
et al., 2013; Lu et al., 2014; Liu et al., 2015). Here we show,
for the first time, the effects of honey-antibiotic combinations
on in vitro established biofilms using MacSynergy II to plot
the entire dose-response landscape. We hypothesized that a
combination of Medihoney, a clinically available honey in a
proprietary formulation, and conventional antibiotics would be
synergistic in their effect on established S. aureus biofilms. We
found, however, that a variety of responses to the Medihoney-
antibiotic combinations occurs, with some being antagonistic,
depending on the antibiotic and concentrations used.
Standing out from this complexity was the Medihoney-
rifampicin combination on established biofilms. Rifampicin
alone did not have very high potency against biofilms, but was
drastically altered in the presence of honey showing strong
synergistic activity across all honey and drug concentrations
(Figures 1, 2). Analysis of the checkerboard data for biofilm
biomass reduction using MacSynergy II indicated this synergy
was strong enough to expect it to be significant in vivo (Figure 3,
Table 1). Accordingly, cell viability was significantly reduced and
there was a marked reduction in the live-cell biofilm density
(Figure 4). These findings support our previous reports of
synergism between Medihoney and rifampicin against S. aureus
in planktonic and biofilm form (Müller et al., 2013; Liu et al.,
2015). Rifampicin as a treatment on its own has been associated
with the rapid emergence of resistance in S. aureus (Raad
et al., 2007), but has been identified as an anti-staphylococcal
antibiotic enhancer in combination therapies with vancomycin,
tetracycline, gentamicin, fusidic acid, oxacillin, ciprofloxacin,
and cefazolin (Monzón et al., 2001; Saginur et al., 2006; Raad
et al., 2007). For example, a rifampicin-vancomycin combination
was found to have increased efficacy against S. aureus biofilms,
purportedly because the drugs had complementary killing
activity whereby vancomycin was more effective at eradicating
early stage biofilms and rifampicin on mature biofilms (Monzón
et al., 2001). One proposed reason for rifampicin acting as
an enhancer in anti-biofilm drug combinations has been that
rifampicin acts to decrease adherence of biofilm organisms to
surfaces, causing the release of increasing numbers of bacteria
off the biofilm and into broth, therefore allowing the antibiotics
to diffuse and kill the bacterial cells (Monzón et al., 2001;
Saginur et al., 2006). Additionally, it has been proposed that
the bactericidal, rather than bacteriostatic, activity of rifampicin
aids in synergistic activity (Monzón et al., 2001). Our findings
also give weight to these studies, identifying rifampicin as a
superior candidate for combinational approaches in preventing
and eradicating staphylococcal biofilms. The use of in vivo
approaches, such as wound or animal models, to demonstrate
the synergistic effects of the Medihoney-rifampicin combination
would further support the prediction power of the in vitro studies
performed here.
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FIGURE 4 | Effects of Medihoney and antibiotic combinations on cell viability within biofilms and on biofilm structure. Medihoney (MD) was tested in combination with
each of three antibiotics: (A) Rifampicin (RIF); (B) Fusidic Acid (FUS); (C) Clindamycin (CLD). Left panels: viable cells remaining within the established biofilm following
treatment with Medihoney-antibiotic combinations were evaluated using the BacTiter-Glo assay, which measures the production of ATP. The percentage of viable cells
was calculated relative to the untreated control, which was set at 100%. Statistical significance (p < 0.05) was assessed by one-way ANOVA with a Tukey post-hoc
test. Medihoney-fusidic acid was the only tested combination found to be not significant (NS). Right panel: 3-D images produced by confocal laser scanning
microscopy of established biofilm after combination treatment. Biofilms were stained with SYTOTM 9 (green = viable cells). Both the thickness and structure of the
established biofilms were notably reduced after treatment by Medihoney-rifampicin and Medihoney-clindamycin. Scale bar represents 10µm.
For the other Medihoney-antibiotic combinations, the results
were very different. Some Medihoney-antibiotic combinations
were antagonistic (gentamicin and oxacillin), and some (fusidic
acid clindamycin) had both synergistic and antagonistic
interactions depending on the concentrations used (Figure 3).
Antagonism seems to be largely driven by the biofilm-enhancing
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action of honey when used at sub-MIC doses combined with the
ability of the antibiotic to counteract this effect. For example,
gentamicin cannot counteract this biofilm-enhancing action
and all concentrations of it largely parallel the honey response
(Figure 2). Clindamycin, fusidic acid, and oxacillin have an
intermediate ability to reduce the biofilm-enhancing action, and
this increases with increased concentrations of antibiotic. The
biofilm-enhancing action of low doses (<MIC) of honey has
been reported previously (Lu et al., 2013), and could be due
to a stress response, which has been observed when bacteria
in biofilms are exposed to sub-inhibitory concentrations of
antibiotics (Haddadin et al., 2010; Subrt et al., 2011; Kaplan et al.,
2012). It should be noted that the biofilm-enhancing action of
sub-inhibitory honey concentrations is not due to the extra sugar
available to the organism as sugar solution controls were not
found to enhance biofilm (Lu et al., 2013).
Previous studies have investigated the effect of Medihoney-
antibiotic combinations on S. aureus, both in the planktonic
state and on biofilm formation (Liu et al., 2015). The type of
effect—as determined by FICI analysis of Medihoney-antibiotic
combinations—was found to be identical for planktonic growth
and biofilm formation and no antagonism was observed
for any combination studied. Synergy was observed between
Medihoney and each of oxacillin, clindamycin and rifampicin.
The Medihoney-gentamicin combination however showed no
synergistic activity, nor did it show antagonism (fusidic acid
was not tested). This unity of effect contrasts with the complex
effects observed in the current study using established S. aureus
biofilms (Table 1), however one point of clear consistency
is the strong synergy produced by Medihoney-rifampicin
combinations against S. aureus, whether planktonic or in
biofilms.
This is, to our knowledge, the first study to examine the honey-
antibiotic interactions using MacSynergy II. By simultaneously
visualizing antagonistic and synergistic areas in the same plot,
MacSynergy II makes it possible to find a combined drug dose
that shows synergy which can be overlooked when using a single
value, such as the FICI. This was particularly useful because
of the observation that sub-inhibitory levels of Medihoney
or antibiotics actually enhance rather than reduce biofilms,
therefore analyses that rely on generating one overall synergy
score (e.g., FICI) may distort our ability to detect synergy when
it does happen. For example, fusidic acid and clindamycin, which
are of intermediate potency when used alone, showed improved
anti-biofilm activity when combined with Medihoney, generally
following a dose-dependent manner (Figures 2, 3). MacSynergy
II analyses are therefore useful for informing the correct doses
to use in order to enhance the anti-biofilm activity of these
inhibitors.
The importance of assessing cell viability and visually
inspecting biofilms is best demonstrated by the effects of the
Medihoney-clindamycin treatment. In this example, an overall
antagonistic effect was assigned when the biofilm reduction data
were analyzed with MacSynergy II (Figure 3, Table 1). However,
confocal microscopy revealed a visible reduction in biofilm
cover and a significant reduction in viability of cells in the
remaining biofilm following treatment with 8% w/v Medihoney
and 0.04µg/ml clindamycin (Figure 4C). Additionally,
treatment with Medihoney-fusidic acid at concentration
pairs showing synergistic activity in reducing biofilm biomass
(8% honey−0.02µg/ml drug; 8% honey−0.04µg/ml drug)
still left viable cells in the remaining biofilm (Figure 4B).
Therefore, visualizing the biofilms and assessing cell
viability also play an integral part in identifying synergistic
combinations.
Our results using established biofilms do not show the
same synergy patterns as seen with planktonic cells or biofilm
prevention (Liu et al., 2015). This is likely due to the
different physiology and metabolism in the biofilms, and the
different pathways controlling this specialized differentiation
event. The dose-response methods used in this study are
not able to identify the potential mechanism for Medihoney-
antibiotic combinations. It has been previously suggested that the
synergistic effect of Medihoney in combination with clindamycin
may be due to both honey and drug acting on sequential or
orthogonal steps of the protein synthesis pathway, shutting
it down more effectively (Liu et al., 2015). For example,
clindamycin inhibits bacterial cell growth by targeting the
50S subunits of the ribosome and honey (manuka) alters the
levels of protein synthesis components, including ribosomal
proteins (Blair et al., 2009; Packer et al., 2012). However, these
genomic studies with honey were performed with bacteria in
the planktonic state and it is likely that the mechanism for the
interaction of Medihoney and antibiotics differs when bacteria
are in the biofilm state. One possible explanation for the
synergistic activity of the Medihoney-rifampicin combination
seen here could be that they target the same pathway (i.e.,
transcription- RNA polymerase). Further investigation of the
mechanism underlying synergism observed in this study may
inform development of Medihoney-drug combinations for
treatment of established biofilms in chronic wounds. The
variation in honey-antibiotic interactions we observe here could
be due to the varying nature of the drugs, their ability to
penetrate the biofilm, and their different modes of action. The
honey-antibiotic interactions may provide insight into the mode
of action of honey, i.e., honey-antibiotic combinations with
synergistic activity may have a similar mode of action, and
those combinations with antagonistic activity have different ones.
This effect has previously been noted in interaction studies
between the essential oil of Ocimum basilicum (basil) and
antibiotics imipenem and ciprofloxacin, showing synergistic and
antagonistic activity, respectively (Araújo Silva et al., 2016).
In conclusion, our results demonstrate that the Medihoney-
rifampicin combination was superior to combinations using the
other antibiotics against established S. aureus biofilms. This adds
to the synergistic activity of this combination treatment across
planktonic growth and biofilm prevention (Müller et al., 2013;
Liu et al., 2015), thus supporting the use of honey as an adjunct
treatment with rifampicin for chronic wounds. We also show
that MacSynergy II provides a valuable platform for analyzing
synergistic activity between honey-antibiotic combinations, and
when coupled with visual inspection of the biofilms can
give a comprehensive assessment of combination therapies for
clinical use.
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